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Dysregulation of fragile X mental retardation
protein and metabotropic glutamate receptor 5
in superior frontal cortex of individuals with
autism: a postmortem brain study
S Hossein Fatemi1,2,3* and Timothy D Folsom1
Abstract
Background: Fragile X syndrome is caused by loss of function of the fragile X mental retardation 1 (FMR1) gene
and shares multiple phenotypes with autism. We have previously found reduced expression of the protein product
of FMR1 (FMRP) in vermis of adults with autism.
Methods: In the current study, we have investigated levels of FMRP in the superior frontal cortex of people with
autism and matched controls using Western blot analysis. Because FMRP regulates the translation of multiple
genes, we also measured protein levels for downstream molecules metabotropic glutamate receptor 5 (mGluR5)
and g-aminobutyric acid (GABA) A receptor b3 (GABRb3), as well as glial fibrillary acidic protein (GFAP).
Results: We observed significantly reduced levels of protein for FMRP in adults with autism, significantly increased
levels of protein for mGluR5 in children with autism and significantly increased levels of GFAP in adults and
children with autism. We found no change in expression of GABRb3. Our results for FMRP, mGluR5 and GFAP
confirm our previous work in the cerebellar vermis of people with autism.
Conclusion: These changes may be responsible for cognitive deficits and seizure disorder in people with autism.
Background
Autism and fragile X syndrome (FXS) are two disorders
that share several commonalities, including reduced cer-
ebellar volume, altered dendritic spine morphology
[1-4], presence of seizures, mental retardation and social
anxiety [2-5], as well as other behavioral abnormalities
[5,6]. People with both FXS and autism have been
shown to have lower IQ scores [7], lower adaptive skills
[7], lower expressive language skills [8] and greater
autonomic dysfunction and hyperarousal [9] than people
with FXS alone. The rate of FXS in people with autism
varies from 2% to 8% [10,11]. The prevalence of autism
in people with FXS has been estimated to be anywhere
from 25% to 47% [5,12,13].
All diagnoses of FXS require loss of function mutation
of the fragile X mental retardation 1 (FMR1) gene [14].
The product of the FMR1 gene, fragile X mental retar-
dation protein (FMRP), has roles in multiple intranuc-
lear and posttranscriptional events [15,16] and has been
shown to bind to up to 4% of the mRNA expressed in
the brain [17]. FMRP is thought to be involved in multi-
ple developmental events, including normal differentia-
tion, migration of subpopulations of neuronal cells and
the development of cortical circuits [18]. FMRP may
also have roles in synaptic pruning [19], and the results
of multiple studies have supported a role for FMRP in
synaptic plasticity [17,20]. All of these functions are
relevant to the pathology of autism. Any abnormality in
FMRP function could affect multiple genes and path-
ways [21]. For example, reduced FMRP expression has
been shown to negatively affect the expression of g-ami-
nobutyric acid A (GABAA) receptors in FXS animal
models [22-24], and work done at our laboratory has
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shown significant reductions in protein for both FMRP
and the GABAA, b3 subunit (GABRb3) in vermis of
adults with autism [25].
In vermis of people with autism, our laboratory has
recently demonstrated the following: (1) reduction in
levels of FMRP and GABRb3 in adults with autism, (2)
increased expression of metabotropic glutamate receptor
5 (mGluR5) in children with autism and (3) increased
glial fibrillary acidic protein (GFAP) in children and
adults with autism [25]. In the current study, we have
expanded our research to measure protein levels for the
same molecules in the superior frontal cortex (Brod-
mann’s area 9 (BA9)). We hypothesized that FMRP
would be reduced, potentially explaining deficits that are
common in autism spectrum disorder and FXS.
Methods
Tissue preparation
All experimental procedures were approved by the Insti-
tutional Review Board of the University of Minnesota
School of Medicine. Postmortem blocks of superior
frontal cortex (that is, BA9) were obtained from the
National Institute of Child Health & Human Develop-
ment Brain and Tissue Bank for Developmental Disor-
ders, University of Maryland, Baltimore, MD, USA; the
Harvard Brain Tissue Resource Center, which is sup-
ported in part by Public Health Service grant R24
MH068855; the Brain Endowment Bank, which is
funded in part by the National Parkinson Foundation,
Inc., Miami, FL, USA; and the Autism Tissue Program.
The tissue samples (Table 1) were prepared as described
previously [25-28]. Sample B6184 was tested for FXS,
and the test results were negative. There are no records
to indicate that any of the other individuals received
genetic testing for, or were diagnosed with, FXS, dupli-
cation at chromosome 15q or any other relevant genetic
abnormalities that could contribute to the pathology of
autism.
Sodium dodecyl sulfate polyacrylamide gel
electrophoresis and Western blot analysis
Tissue samples from BA9 (adults: n = 5 controls, n = 8
autistic; children: n = 5 controls, n = 12 autistic) were
prepared and subjected to sodium dodecyl sulfate polya-
crylamide gel electrophoresis (SDS-PAGE) and Western
blot analysis as described previously [25-28]. For FMRP
and mGluR5, 6% resolving gels were used. For GABRb3,
GFAP and neuron-specific enolase (NSE), 10% resolving
gels were used. Following SDS-PAGE, proteins were
transferred onto nitrocellulose membranes for 2 hours
at 300 mA. Western blots were blocked for 1 hour at
room temperature (RT) followed by overnight incuba-
tion in primary antibodies at 4°C. The primary antibo-
dies used were anti-FMRP (1:5,000; Millipore, Billerica,
MA, USA) anti-mGluR5 (1:300; Abcam Inc., Cambridge,
MA, USA), anti-GABRb3 (1:1,000; Novus Biologicals,
Littleton, CO, USA), anti-GFAP (1:2,000; Sigma-Aldrich,
St. Louis, MO, USA), anti-NSE (1:2,000; Abcam Inc.)
and anti-b-actin (1:5,000; Sigma-Aldrich). Blots were
incubated in primary antibodies overnight at 4°C. Fol-
lowing a 30-minute wash in phosphate-buffered saline
supplemented with 0.003% Tween 20 (PBST), blots were
incubated in secondary antibodies for 60 minutes at
room temperature. Secondary antibodies used were
A9169 (goat antirabbit immunoglobulin G (IgG),
1:80,000; Sigma-Aldrich) and A9044 (rabbit antimouse
IgG, 1:80,000; Sigma-Aldrich). Blots were washed twice
in PBST, and bands were visualized using the ECL Plus
Western Blotting detection system (GE Healthcare, Lit-
tle Chalfont, Buckinghamshire, UK) and exposed to CL-
XPosure Film (Thermo Scientific, Rockford, IL, USA).
Immunoreactive bands were quantified using back-
ground subtraction with a Bio-Rad densitometer and
Bio-Rad Multi-Analyst software (Bio-Rad, Hercules, CA,
USA). with the following approximate molecular
weights: 224 kDa (dimer) and 112 kDa (monomer) for
mGluR5; 73 kDa for FMRP; 52 kDa for GABRb3 (We
have observed a range of molecular weights for
GABRb3 including 52 kDa and 56 kDa which agrees
with the expected molecular weight of 51-56 kDa
according to the antibody data sheet from Novus Biolo-
gicals, Inc. and from previously published results
[29-31]); 50, 46, 42 and 38 kDa for GFAP (all bands
measured together); 46 kDa for NSE; and 42 kDa for b-
actin. The results obtained were based on at least two
independent experiments.
Statistical analysis
Statistical analysis of protein data was performed as pre-
viously described [26,27]. We investigated the potential
confounding effects of age, postmortem interval and
gender by examining group differences with postmortem
intervals as covariates. We further analyzed data on the
basis of stratification by age groups, that is, adults (older
than 18 years of age) and children (ages 18 and
younger). Effect sizes were calculated using Cohen’s d
statistic, with values >0.8 considered a large effect [32].
Results
All values derived using Western blot analysis were nor-
malized against two housekeeping proteins: NSE and b-
actin. Previous studies of FMRP have shown that two to
five distinct bands of FMRP may appear on SDS-PAGE
and Western blots which are produced by alternative
splicing of the FMR1 gene [33,34]. We observed up to
two bands, which were measured together. We observed
that there were significant reductions in the FMRP/NSE
ratio (55%, P < 0.017) and the FMRP/b-actin ratio (50%,
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Table 1 Demographic data for people with autism and healthy controlsa
Case Dx Sex Age PMI,
hours
Ethnicity Medication History Cause of Death Seizure MR
4670 Control M 4 17 Caucasian None Commotio Cordis No No
1674 Control M 8 36 Caucasian None Drowning No No
4787 Control M 12 15 African
American
Montelukast, Albuteral, Prednisone, Loratadine Asthma No No
1823 Control M 15 18 Caucasian None MVA No No
6396 Control M 18 19.83 Unknown None Unknown No No
1846 Control F 20 9 Caucasian None MVA No No
6316 Control F 32 28.92 Unknown None Unknown No No






1376 Control M 37 12 African
American
None ASCVD No No
6420 Control M 41 30.4 Unknown None Heart Attack No No
7002 Autism F 5 32.73 Asian None Drowning No No
5569 Autism M 5 39 Caucasian None Drowning No No
1174 Autism F 7 14 Caucasian None Seizure disorder Yes No
5666 Autism M 8 22.16 Caucasian None Cancer Yes No
4231 Autism M 8 12 African
American
Olanzapine, Galantamine Drowning No Yes
4925 Autism M 9 27 Caucasian Clonidine, Sodium valproate, Phenytoin, Lamotrigine,
Methylphenidate, Carbamazepine
Seizure disorder Yes No
4899 Autism M 14 9 Caucasian None Drowning No No
6184 Autism F 18 6.75 Caucasian None Seizure disorder Yes No
5144 Autism M 20 23.66 Caucasian Erythromycin gel, Minocycline MVA No Yes
1638 Autism F 20 50 Caucasian None Seizure disorder Yes Yes
6337 Autism M 22 25 Caucasian Aripiprazole, Lamotrigine, Zonisamide Aspiration Yes No
6994 Autism M 29 43.25 Caucasian Fexofenadine, Ziprasidone HCl, Carbamazepine Seizure (suspected) Yes No
6640 Autism F 29 17.83 Caucasian Fluvoxamine Seizure disorder Yes No
6677 Autism M 30 16.06 Caucasian None Heart Failure
(congestive)
No No
5173 Autism M 30 20.33 Caucasian Cisapride, Clorazepate, Sodium valproate, Phenytoin, Folic











6401 Autism M 39 13.95 Caucasian None Cardiac Tamonade No No
5562 Autism M 39 22.75 Caucasian None Sudden
unexpected death
Yes No
6469 Autism F 49 16.33 Caucasian Wafarin, Venlafaxine, Erythromycin, Lansoprazole, Risperidone,
Metformin, Gabapentin, Propranolol, Levothyroxine
Pulmonary Arrest No Yes





Children Control Autistic Change P value Cohen’s d
Age ± SD
(years)
11.4 ± 5.55 9.25 ± 4.53 ↓18.9% ns –
PMI ± SD
(years)
21.2 ± 8.47 18.6 ± 9.47 ↓12.3% ns –
Gender 5M 5M:3F – – –
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P < 0.042) in BA9 of adults with autism compared with
controls (P < 0.026) (Figure 1 and Tables 2 and 3). In
BA9 of children with autism, there were significant
increases in the dimerized mGluR5/NSE ratio (159%, P
< 0.013) and total mGluR5/NSE ratio (165%, P < 0.014)
(Figure 2 and Table 2). Similarly, there were significant
increases in both the dimerized mGluR5/b-actin ratio
(168%, P < 0.023) and the total mGluR5/b-actin ratio
(191%, P < 0.011) (Table 3). We previously observed a
significant difference in dimerized mGluR5 vs. total
mGluR5 in vermis of children with autism [25]; how-
ever, a similar result was not seen in BA9 (Table 2).
GFAP was found to be significantly elevated in BA9 of
both children (136%, P < 0.012) and adults (58%, P <
0.033) with autism (Figure 3 and Tables 2 and 3). We
observed no significant differences in protein levels for
NSE (Figure 3 and Table 2) or b-actin (Figure 3 and
Table 3), suggesting that the observed changes were not
due to changes in neuronal cell numbers between peo-
ple with autism and matched controls. Finally, there was
no significant change in GABRb3 between people with
autism and matched controls (Figure 4 and Tables 2
and 3), despite large effect sizes.
There were no significant differences between indivi-
duals with autism and controls related to age or post-
mortem interval (PMI) (Tables 2 and 3). We examined
the confounding effects of age and PMI on our results
and found no impact of age on the levels of any proteins
(data not shown). There was an impact of PMI on the
FMRP/b-actin ratio. However, as there was no signifi-
cant difference in PMI between the two groups, the
impact of PMI on the FMRP/b-actin ratio was not
meaningful.
The effect of gender was examined in both children
and adults. For children, there were no girls in the con-
trol group. However, when control boys were compared
with boys with autism, the results for FMRP and
GABRb3 remained nonsignificant and total mGluR5 and
GFAP remained significantly elevated, while the dimer-
ized mGluR5/b-actin ratio lost significance (data not
shown). In adults, it was impossible to evaluate the
effect of gender on levels of FMRP and GFAP owing to
low power, and mGluR5 and GABRb3 remained non-
significant (data not shown).
Mental retardation, seizures and use of anticonvul-
sants were all confounded within the autism group.
Neither seizure disorder nor anticonvulsant use affected
the Western blot analysis results (data not shown). In
comparing people with autism who had seizure disorder
with people with autism without seizure disorder, we
found that there were no significant differences for
FMRP in children, while this comparison could not be
tested in adults because of the low sample size. How-
ever, there was a 47% reduction in FMRP in adults with
autism and seizure disorder compared with adults with
autism without seizure disorder (data not shown). In
only one instance was mental retardation a significant
predictor of differences in Western blot analysis results,
and that was for the GFAP/b-actin ratio in adults.
When that individual (subject 6469) was removed from
the analysis, the difference remained significant between
people with autism and controls.
Effect sizes were calculated for the comparisons using
Cohen’s d statistic where an effect size >0.8 is consid-
ered a large effect [32]. In children, the comparisons of
mGluR5 dimer/NSE ratio, mGluR5 total/NSE ratio,
GABRb3/NSE ratio, mGluR5 dimer/b-actin ratio,
mGluR5 total/b-actin ratio, GABRb3/b-actin ratio and
GFAP/b-actin ratio displayed large effect sizes (Tables 2
and 3). In adults, the comparisons of FMRP/NSE ratio,
mGluR5 total/NSE ratio, FMRP/b-actin ratio, mGluR5
dimer/b-actin ratio, mGluR5 total/b-actin ratio and
GFAP/b-actin ratio between the two groups consisted of
large or very large effect sizes (Tables 2 and 3).
Discussion
In the current study, we found reduced protein expres-
sion of FMRP in BA9 of adults with autism, increased
expression of mGluR5 in children with autism, increased
expression of GFAP in both children and adults with
autism and no significant difference in GABRb3 expres-
sion. With the exception of no change in GABRb3
expression, these changes in the prefrontal cortex (PFC;
that is, BA9) mirror what we have previously observed
in cerebellar vermis of people with autism [25].
We are the first to demonstrate significant changes in
protein for FMRP in BA9 of adults with autism. Recent
imaging studies have shown reduced activation of the
Table 1 Demographic data for people with autism and healthy controlsa (Continued)
Adults Control Autistic Change P value Cohen’s d
Age ± SD
(years)
32.6 ± 7.89 33.3 ± 11.2 ↑2.1% ns –
PMI ± SD
(years)
21.5 ± 10.1 24.6 ± 11.1 ↑14.4% ns –
Gender 3M:2F 9M:3F – – –
aDx, diagnosis; PMI, postmortem interval; MVA, motor vehicle accident; MR, mental retardation; ns, not significant.
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PFC during cognitive performance tasks in individuals
with FXS [35-37]. Hoeft et al. [36] found reduced acti-
vation in the right ventrolateral PFC in adolescent boys
with FXS during a go vs. no go executive function task.
Similarly, in a study of females with FXS, there was
reduced activation of the PFC and striatum during a
working memory task [35]. Reduced activation of the
PFC has also been shown in females with FXS during
mathematical processing [37]. Taken together, these stu-
dies indicate impairment of multiple PFC-mediated
functions in people with FXS. The reduction in FMRP
in BA9 in adults with autism may result in similar
changes in brain activation and cognitive processing in
individuals with autism.
Dopamine plays a critical role in cognitive functions in
the PFC [38,39], and recent studies involving Fmr1-
knockout mice have shown a role of FMRP in dopamine
modulation in the PFC [40,41]. Such a role for FMRP
may help to explain learning and memory deficits in
people with FXS [40,41]. Our finding of reduced FMRP
expression in BA9 of adults may help to explain cogni-
tive deficits in people with autism.
Figure 1 Expression of FMRP in superior frontal cortex of people with autism and matched controls.(A) Representative samples of fragile
X mental retardation protein (FMRP) from controls (C) and people with autism (A). (B) Mean FMRP/neuron-specific enolase (NSE) ratios for
people with autism (filled histogram bars) and controls are shown for Brodmann’s area 9 (BA9). (C) Mean FMRP/b-actin ratios for people with
autism (filled histogram bars) and controls are shown for BA9. Error bars express standard error of the mean. **P < 0.05.
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In contrast to our studies of vermis, we did not
observe a significant reduction in GABRb3 in BA9 of
adults with autism. However, previous experiments in
our laboratory using a different set of BA9 tissue from
controls and individuals with autism also failed to show
any significant difference in protein expression of
GABRb3 (SHF and TJ Reutiman, unpublished data).
These results may reflect regional differences in
GABRb3 protein expression in the brains of people with
autism.
Our finding regarding GFAP confirms our earlier
findings of significant elevation of GFAP in BA9 of a
different set of people with autism [42]. This increased
level of GFAP is consistent with previous findings of
astroglial activation in the brains of individuals with
autism [43-45], suggesting dysregulation of the
immune system. Coexpression of GFAP and FMRP has
been demonstrated by immunocytochemical studies in
the hippocampi of embryonic and postnatal mice, but
not in adults [46,47]. Significantly increased GFAP has
been observed in the cerebellum [48] and in the stria-
tum, hippocampus, and cerebral cortex [49] of fragile
X-knockout mice. Ellegood et al. [48] suggested that
the loss of FMRP and increase in cerebellar GFAP
could contribute to anatomical changes in the
cerebellum.
The significant elevation of mGluR5 protein in chil-
dren with autism is an interesting finding in light of the
connection between group 1 mGluRs and FMRP in
FXS, which are believed to act in opposition to one
another. It has been proposed that in the absence of
FMRP, unchecked mGluR-dependent protein synthesis
leads to the pathology of FXS [50,51]. A number of
recent findings in Fmr1-knockout mice have shown that
Table 2 Western blot analysis results for FMRP, mGluR5, GABRb3 and NSE and their ratios in BA9a
Children Control Autistic Change P value Cohen’s d
FMRP/NSE 0.08 ± 0.057 0.123 ± 0.069 ↑53% ns 0.66
mGluR5 dimer/NSE 0.158 ± 0.175 0.409 ± 0.101 ↑159% 0.013b 1.93b
mGluR5 total/NSE 0.167 ± 0.182 0.443 ± 0.123 ↑165% 0.014b 1.90b
mGluR5 dimer/mGluR5 total 0.867 ± 0.154 0.93 ± 0.042 ↑7.2% ns 0.66
GABRb3/NSE 0.095 ± 0.052 0.161 ± 0.086 ↑69% ns 0.86b
NSE 17.4 ± 0.642 19.20 ± 2.67 ↑10.4% ns –
Adults Control Autistic Change P value Cohen’s d
FMRP/NSE 0.24 ± 0.094 0.107 ± 0.068 ↓55% 0.017b 1.74b
mGluR5 dimer/NSE 0.186 ± 0.098 0.309 ± 0.188 ↑66% ns 0.74
mGluR5 total/NSE 0.191 ± 0.099 0.367 ± 0.187 ↑92% ns 1.05b
mGluR5 dimer/mGluR5 total 0.974 ± 0.023 0.982 ± 0.011 ↑0.8% ns 0.50
GABRb3/NSE 0.177 ± 0.082 0.186 ± 0.103 ↑5.1% ns 0.09
NSE 17.5 ± 3.17 18.8 ± 2.3 ↑1.3% ns -
aFMRP, fragile X mental retardation protein; mGluR5, metabotropic glutamate receptor 5; GABRb3, g-aminobutyric acid (GABA) A receptor b3; NSE, neuron-specific
enolase; BA9, Brodmann’s area 9; ns, not significant; bstatistically significant.
Table 3 Western blot analysis results for FMRP, mGluR5, GABRb3, GFAP and b-actin and their ratios in BA9a
Children Control Autistic Change P value Cohen’s d
FMRP/b-actin 0.073 ± 0.054 0.119 ± 0.062 ↑63% ns 0.76
mGluR5 dimer/b-actin 0.151 ± 0.179 0.405 ± 0.131 ↑168% 0.023b 1.71b
mGluR5 total/b-actin 0.16 ± 0.187 0.466 ± 0.131 ↑191% 0.011b 2.01b
GABRb3/b-actin 0.085 ± 0.049 0.187 ± 0.128 ↑120% ns 0.96b
GFAP/b-actin 1.6 ± 1.16 3.78 ± 0.962 ↑136% 0.012b 2.09b
b-actin 20.1 ± 2.94 18.3 ± 4.79 ↓8.9% ns -
Adults Control Autistic Change P value Cohen’s d
FMRP/b-actin 0.175 ± 0.075 0.087 ± 0.055 ↓50% 0.042b 1.43b
mGluR5 dimer/b-actin 0.136 ± 0.069 0.267 ± 0.175 ↑96% ns 0.87b
mGluR5 total/b-actin 0.139 ± 0.069 0.272 ± 0.178 ↑96% ns 0.87b
GABRb3/b-actin 0.136 ± 0.069 0.159 ± 0.087 ↑17% ns 0.27
GFAP/b-actin 1.93 ± 0.762 3.04 ± 0.758 ↑58% 0.033b 1.46b
b-actin 23.2 ± 1.97 21.7 ± 3.28 ↓6.5% ns -
aFMRP, fragile X mental retardation protein; mGluR5, metabotropic glutamate receptor 5; GABRb3, g-aminobutyric acid (GABA) A receptor b3; GFAP, glial fibrillary
acidic protein; BA9, Brodmann’s area 9; ns, not significant. bstatistically significant.
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Figure 2 Expression of mGluR5 in superior frontal cortex of people with autism and matched controls.(A) Representative samples of
metabotropic glutamate receptor 5 (mGluR5) from controls (C) and people with autism (A). (B) Mean mGluR5 dimer and monomer/neuron-
specific enolase (NSE) ratios for people with autism (filled histogram bars) and controls are shown for Brodmann’s area 9 (BA9). (C) Mean
mGluR5/b-actin ratios for people with autism (filled histogram bars) and controls are shown for BA9. Error bars express standard error of the
mean. **P < 0.05.
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the use of mGluR5 inhibitors, such as 2-methyl-6-(phe-
nylethynyl)-pyridine (MPEP), rescues FXS phenotypes
[52,53]. Recent experiments by Silverman et al. [54,55]
have shown that MPEP was useful in the treatment of
repetitive grooming behavior in the BTBR mouse model
of autism by antagonizing mGluR5 receptors. This new
model adds to the previous animal models for autism
and FXS and helps to expand our understanding of the
role of mGluR5 dysfunction.
The increased expression of mGluR5 in children with
autism suggests pathologic activation of mGluR5 which
may be prenatal or early postnatal. This activation may
lead to seizures, cognitive problems and perhaps brain
morphological abnormalities in children with autism
and FXS. While FMRP levels are similar in children
with autism and controls, overactive mGluR5 signaling
may be strong enough to overcome FMRP’s inhibitory
effect. In adults, there continue to be elevated levels of
dimerized mGluR5 (66% increase for mGluR5/NSE ratio
and 92% increase for mGluR5/b-actin ratio) and total
mGluR5 (96% increase for both mGluR5/NSE and
mGluR5/b-actin ratios), although they do not reach the
level of statistical significance. At the same time, adults
with autism have significantly lower levels of FMRP.
This reduction in FMRP reduces its inhibitory effect on
mGluR5 signaling, resulting in a continuation of the
phenotypes observed in children with autism and FXS.
The interaction between FMRP and mGluR5 also pre-
sents a potential means of treatment using allosteric
modulators of mGluR5. In a pilot study, treatment of
patients with FXS with lithium, which reduces mGluR-
activated translation, led to improved scores on the
Figure 3 (A) Representative samples of glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE) and b-actin from controls
(C) and people with autism (A). (B) Mean GFAP/b-actin ratios for people with autism (filled histogram bars) and controls are shown for
Brodmann’s area 9 (BA9). Error bars express standard error of the mean. **P < 0.05.
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Aberrant Behavior Checklist-Community Edition and
was well-tolerated [56]. Additionally, fenobam, an anxio-
lytic drug that acts as an inhibitor of mGluR5 [57], has
been shown to correct prepulse inhibition deficits in
people with with FXS in a recent open-label pilot study
[58]. Norbin is a positive modulator of endogenous
mGluR5 that enhances mGluR5 signaling [59]. Reduc-
tion in norbin has been shown to lead to a consequent
reduction in mGluR5 expression, and norbin-knockout
mice show enhanced locomotor activity similar to that
of mice treated with MPEP [59]. It may be the case that
allosteric modulators of mGluR5 or targeting of natu-
rally occurring modulators of mGluR5 could have simi-
lar effects on people with autism and warrant future
exploration. A further avenue of treatment may be the
use agents which raise the levels of GABA in the brains
of individuals with autism. Recently, Heulens et al. [60]
reported on ganaxolone as a potential GABAA receptor
agonist in the treatment of people with FXS. Certainly
this agent, as well as GABAB receptor agonists such as
arbaclofen, could be investigated in the treatment of
autism.
Figure 4 Expression of GABRb3 in superior frontal cortex of people with autism and matched controls. (A) Representative samples of g-
aminobutyric acid (GABA) A receptor b3 (GABRb3) from controls (C) and people with autism (A). (B) Mean GABRb3/neuron-specific enolase
(NSE) ratios for people with autism (filled histogram bars) and controls are shown for Brodmann’s area 9 (BA9). (C) Mean GABRb3/b-actin ratios
for people with autism (filled histogram bars) and controls are shown for BA9. Error bars express standard error of the mean.
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Conclusions
We observed reduced expression of FMRP in BA9 of
adults with autism, and increased expression of mGluR5
in children with autism, compared with matched controls.
These findings mirror results observed in our laboratory
in cerebellar vermis of people with autism. These observed
changes in protein expression of FMRP in adults and
mGluR5 in children are likely to contribute to cognitive
deficits and the presence of comorbid seizure disorder in
individuals with autism. The interaction between FMRP
and mGluR5 provides a potential avenue for treatment
through the use of allosteric modulators.
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